# The Role of CYP8B1 Polymorphisms in Modulating the Biochemical Pathways Affected by SGLT2 Inhibitors in T2DM and Obesity

Study · id `cardio:ct-nct07120828` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07120828](<https://clinicaltrials.gov/study/NCT07120828>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07120828

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 260 participants.

## Technical summary

Registry record NCT07120828. Randomized; no masking; primary purpose treatment. Start 2025-07-15 (actual); primary completion 2025-08-30 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 260 participants (enrolled count; ClinicalTrials.gov record NCT07120828, source copy `cardio:ctgov-nct07120828-2026-03-17`, retrieved 2026-10-26)
- Started: 2025-07-15 (actual) (ClinicalTrials.gov record NCT07120828, source copy `cardio:ctgov-nct07120828-2026-03-17`, retrieved 2026-10-26)
- Primary completion: 2025-08-30 (actual) (ClinicalTrials.gov record NCT07120828, source copy `cardio:ctgov-nct07120828-2026-03-17`, retrieved 2026-10-26)
- Completion: 2026-03-15 (actual) (ClinicalTrials.gov record NCT07120828, source copy `cardio:ctgov-nct07120828-2026-03-17`, retrieved 2026-10-26)
- Countries: Iraq (ClinicalTrials.gov record NCT07120828, source copy `cardio:ctgov-nct07120828-2026-03-17`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07120828-2026-03-17`, retrieved 2026-10-26)

## The registry's words

- Brief title: The Role of CYP8B1 Polymorphisms in Modulating the Biochemical Pathways Affected by SGLT2 Inhibitors in T2DM and Obesity
- Acronym: CYP8B1-SGLT2-T
- Condition: Type 2 Diabetes
- Condition: Obese Diabetics
- Condition: Obese Patients (BMI ≥ 30 kg/m²)
- Intervention (Drug): Empagliflozin (oral)
- Intervention (Drug): Dapagliflozin (DAPA)
- Intervention (Drug): Metfomin
- Lead sponsor: Erbil Polytechnic University
- Lead sponsor class: OTHER
- Collaborator: Kurdistan Higher Council of Medical Specialties
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)

## Provenance

Content hash: ba48a2de53c50cd48bc8d384131434b75b52a10d59daf47a47a7bcf0f6715345
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
